<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00625729</url>
  </required_header>
  <id_info>
    <org_study_id>2007LS064</org_study_id>
    <secondary_id>MT2007-12</secondary_id>
    <secondary_id>UMN-0707M13561</secondary_id>
    <secondary_id>P01CA065493</secondary_id>
    <nct_id>NCT00625729</nct_id>
  </id_info>
  <brief_title>Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia</brief_title>
  <official_title>MT2007-12 Allogeneic Natural Killer Cells With Rituximab in Patients With CD20 Positive Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia. Strategies to Increase Sensitivity of CLL Tumor Cells to Natural Killer Cell-Immune-Mediated Cytolysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Aldesleukin may stimulate natural killer cells to kill cancer cells. Treating&#xD;
      natural killer cells with aldesleukin in the laboratory may help the natural killer cells&#xD;
      kill more cancer cells when they are put back in the body. Giving monoclonal antibodies, such&#xD;
      as rituximab, and chemotherapy drugs, such as fludarabine and cyclophosphamide, before a&#xD;
      donor natural killer cell infusion helps stop the growth of cancer cells. It also helps stop&#xD;
      the patient's immune system from rejecting the donor's stem cells.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying how well giving rituximab and chemotherapy&#xD;
      followed by a donor natural killer cell infusion that has been treated in the laboratory with&#xD;
      aldesleukin followed by aldesleukin works in treating patients with non-Hodgkin lymphoma or&#xD;
      chronic lymphocytic leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To determine if allogeneic natural killer (NK) cells infused following&#xD;
           chemoimmunotherapy can be safely expanded in vivo with aldesleukin.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To determine if interleukin-15 production at day 0 correlates with NK cells expansion.&#xD;
&#xD;
        -  To determine overall response rate at 3 months.&#xD;
&#xD;
        -  To determine time to progression and overall survival.&#xD;
&#xD;
        -  To characterize the quantitative and qualitative toxicities of this treatment plan.&#xD;
&#xD;
        -  To determine the incidence of donor products that do not meet release criteria and the&#xD;
           NK cell numbers infused.&#xD;
&#xD;
        -  To correlate clinical response with donor/recipient KIR ligand matching status, FcG&#xD;
           receptor 3A genotype, and NK cells phenotype and function&#xD;
&#xD;
        -  To determine pharmacodynamic and pharmacogenomic markers and correlate them with NK cell&#xD;
           expansion and disease response.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
        -  Conditioning regimen: Patients receive rituximab intravenously (IV) over 6-8 hours on&#xD;
           days -8, -1, 6, and 13; fludarabine IV on days -6 to -2; and cyclophosphamide IV on day&#xD;
           -5.&#xD;
&#xD;
        -  Allogeneic natural killer (NK) cell administration: Patients receive&#xD;
           aldesleukin-activated haploidentical NK cells IV over less than 1 hour on day 0. Within&#xD;
           4 hours after allogeneic NK cell infusion, patients receive aldesleukin subcutaneously&#xD;
           (SC) 3 times a week for 6 doses. Patients also receive filgrastim (G-CSF) SC beginning&#xD;
           on day 14 and continuing until absolute neutrophil count (ANC) is &gt; 2,500/mm³ for 2&#xD;
           consecutive days.&#xD;
&#xD;
      Patients who achieve a complete or partial response at 28 days are eligible for allogeneic&#xD;
      stem cell transplantation. Patients who achieve initial response at 3 months, clinically&#xD;
      benefit from treatment, but subsequently relapse are eligible for retreatment provided all&#xD;
      eligibility criteria are met.&#xD;
&#xD;
      Blood samples are collected periodically for correlative laboratory studies. Patients with&#xD;
      chronic lymphocytic leukemia (CLL) also undergo bone marrow aspiration periodically for&#xD;
      correlative laboratory studies.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically for up to 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    No patients exhibited natural killer cell expansion (primary endpoint).&#xD;
  </why_stopped>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients Exhibiting Natural Killer Cell Expansion</measure>
    <time_frame>Day 14</time_frame>
    <description>Successful natural killer (NK) cell expansion will be defined as an absolute circulating donor-derived NK cell count of &gt;100 cells/μl 14 days after infusion with &lt;5% donor T and B cells in the mononuclear population.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Interleukin-15 Production and NK Cell Expansion</measure>
    <time_frame>Day 0</time_frame>
    <description>Correlation of interleukin-15 production at day 0 with natural killer (NK) cells expansion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Overall Response</measure>
    <time_frame>3 Months</time_frame>
    <description>Overall response (complete remission plus partial remission) rate at 3 months, as defined by International Working Group for non-Hodgkin lymphoma and NCI Working Group guidelines for chronic lymphocytic leukemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Whose Disease Progressed After Treatment</measure>
    <time_frame>6 Months</time_frame>
    <description>Includes patients (with non-Hodgkin leukemia or chronic lymphocytic leukemia) whose disease progressed after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Adequate Natural Killer Cells Infused</measure>
    <time_frame>Day 0</time_frame>
    <description>Incidence of donor products that met release criteria in accordance with FDA regulations (Lot Release Criteria for allogeneic, interleukin-2 (IL-2) activated natural killer (NK) cell products (BB-IND 8847) and the NK cell numbers infused (donor NK cell dose 1.5-8.0 x 10^7/kg).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Overall Survival</measure>
    <time_frame>6 Months</time_frame>
    <description>Number of patients alive at 6 months after treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Treated Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with donor natural killer cells infusion, rituximab, aldesleukin and chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
    <description>Day 0-14, 10 million international units, 3 times per week for 6 doses</description>
    <arm_group_label>Treated Patients</arm_group_label>
    <other_name>IL-2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>allogeneic natural killer cells</intervention_name>
    <description>Day 0 infusion of cells (1.5-8 x 10^7 cells/kg).</description>
    <arm_group_label>Treated Patients</arm_group_label>
    <other_name>Natural Killer Cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>Administered Day -8, day -1, day +6 and day +13, intravenously (IV) 357 mg/m^2</description>
    <arm_group_label>Treated Patients</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>60 mg/kg intravenous (IV) on Day -5.</description>
    <arm_group_label>Treated Patients</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <description>Day -6 through day -2, 25 mg/m^2 intravenous (IV)</description>
    <arm_group_label>Treated Patients</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient 18 years or older with a diagnosis of non-Hodgkin Lymphoma or chronic&#xD;
             lymphocytic leukemia (NHL or CLL) and one of the following:&#xD;
&#xD;
               -  Progression of NHL following at least 2 prior chemotherapy regimens, (must&#xD;
                  contain rituximab for all NHL and fludarabine for follicular NHL) defined as:&#xD;
&#xD;
                    -  failure to achieve partial remission (PR) with the last chemotherapy&#xD;
&#xD;
                    -  disease progression within 6 months following last chemotherapy&#xD;
&#xD;
               -  Progression of CLL/SLL (small lymphocytic lymphoma) following at least 2 prior&#xD;
                  chemotherapy regimens (containing purine analogs ) in stage Rai III or IV or&#xD;
                  symptomatic disease.&#xD;
&#xD;
               -  Relapsed NHL or CLL following stem cell transplantation for whom the option of&#xD;
                  donor lymphocyte infusion is not available or clinically indicated (e.g.&#xD;
                  recipients of autologous or umbilical cord blood [UCB] transplants).&#xD;
&#xD;
          -  Available related HLA-haploidentical (human leukocyte antigen) natural killer (NK)&#xD;
             cell adult donor by at least Class I serologic typing&#xD;
&#xD;
          -  Karnofsky performance status &gt; 60%&#xD;
&#xD;
          -  Measurable disease based on modified Response Evaluation Criteria In Solid Tumors&#xD;
             (RECIST)&#xD;
&#xD;
          -  Have acceptable organ function as defined within 28 days of enrollment:&#xD;
&#xD;
               -  Hematologic: platelets ≥ 80,000 x 10^9/L; hemoglobin ≥ 9g/dL, unsupported by&#xD;
                  transfusions; absolute neutrophil count (ANC) ≥ 1000 x 10^9/L, unsupported by&#xD;
                  granulocyte-colony stimulating factor or granulocyte-macrophage&#xD;
                  colony-stimulating factor (G-CSF or GM-CS)F for 10 days or Neulasta for 21 days -&#xD;
                  the hematologic requirements are waived for patients with inadequate counts due&#xD;
                  to known bone marrow involvement by lymphoma who are otherwise eligible&#xD;
&#xD;
               -  Renal: glomerular filtration rate (GFR) &gt; 50 ml/min&#xD;
&#xD;
               -  Hepatic: alanine aminotransferase (ALT), aspartate aminotransferase (AST) &lt; 3 x&#xD;
                  upper limit of normal and total bilirubin &lt;3 mg/dl&#xD;
&#xD;
               -  Pulmonary function: &gt;50% corrected carbon monoxide diffusing capacity (DLCO) and&#xD;
                  Forced Expiratory Volume in the first second (FEV1)&#xD;
&#xD;
               -  Cardiac: no symptoms of uncontrolled cardiac disease, left ventricular ejection&#xD;
                  fraction &gt;40%&#xD;
&#xD;
          -  Off prednisone or other immunosuppressive medications for at least 3 days prior to Day&#xD;
             0&#xD;
&#xD;
          -  Women of childbearing potential must agree to use adequate contraception (diaphragm,&#xD;
             birth control pills, injections, intrauterine device [IUD], surgical sterilization,&#xD;
             subcutaneous implants, or abstinence, etc.) for the duration of treatment.&#xD;
&#xD;
          -  Voluntary written informed consent before performance of any study-related procedure&#xD;
             not part of normal medical care.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating. The agents used in this study may be teratogenic to a fetus and&#xD;
             there is no information on the excretion of agents into breast milk. All females of&#xD;
             childbearing potential must have a blood test or urine study within 2 weeks prior to&#xD;
             registration to rule out pregnancy. Women of childbearing age must use appropriate&#xD;
             contraceptive method.&#xD;
&#xD;
          -  Active central nervous system (CNS) lymphoma/leukemia&#xD;
&#xD;
          -  Active serious infection (pulmonary infiltrates or lesions are allowed only after the&#xD;
             appropriate diagnostic testing is negative for infection or appropriate therapy was&#xD;
             initiated for probable infection)&#xD;
&#xD;
          -  Pleural effusion - large enough to be detectable on the chest x-ray&#xD;
&#xD;
          -  Allergy to rituximab or IL-2&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV) and associated non-Hodgkins lymphoma (NHL)&#xD;
&#xD;
          -  Active concurrent malignancy (except skin cancer) requiring systemic therapy in the&#xD;
             past 2 years&#xD;
&#xD;
          -  Epstein-Barr virus (EBV) post-transplant lymphoproliferative disorder&#xD;
&#xD;
          -  Positive hepatitis B surface antigen (HBsAg). If Hepatitis B core antibody (HBcAb) is&#xD;
             positive, Hepatitis B deoxyribonucleic acid (DNA) by polymerase chain reaction (PCR)&#xD;
             will be evaluated. Positive anti HBcAb and undetectable viral load does not exclude&#xD;
             the patient.&#xD;
&#xD;
          -  Any experimental therapy in the past 30 days&#xD;
&#xD;
        Donor Selection:&#xD;
&#xD;
          -  Related donors (sibling, parent, offspring, parent or offspring of an HLA identical&#xD;
             sibling) ≥ age 18 years&#xD;
&#xD;
          -  Able and willing to undergo lymphapheresis&#xD;
&#xD;
          -  HLA-haploidentical donor/recipient match. If time permits and multiple donors are&#xD;
             available, preference will be given to the Killer-cell Immunoglobulin-like Receptors&#xD;
             (KIR) ligand mismatched donor (as predicted by HLA typing).&#xD;
&#xD;
          -  HIV-1, HIV-2 negative, Human T-lymphotropic virus Type I (HTLV-1), HTLV-2 negative,&#xD;
             West Nile virus (WNV) negative, Hepatitis B and C negative&#xD;
&#xD;
          -  Adequate organ function defined as:&#xD;
&#xD;
               -  Hematologic: CBC/diff/platelet count near normal limits,&#xD;
&#xD;
               -  Hepatic: ALT &lt; 2 x upper limit of normal,&#xD;
&#xD;
          -  Not pregnant or lactating&#xD;
&#xD;
          -  In general good health as determined by the study physician&#xD;
&#xD;
          -  Able to give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Veronika Bachanova, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Masonic Cancer Center, University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Masonic Cancer Center, University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <study_first_submitted>February 26, 2008</study_first_submitted>
  <study_first_submitted_qc>February 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 28, 2008</study_first_posted>
  <results_first_submitted>July 2, 2010</results_first_submitted>
  <results_first_submitted_qc>July 2, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 30, 2010</results_first_posted>
  <last_update_submitted>December 3, 2017</last_update_submitted>
  <last_update_submitted_qc>December 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
  <keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
  <keyword>Waldenstrom macroglobulinemia</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Patients Treated With Natural Killer Cells</title>
          <description>Patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with 1 dose donor natural killer cells infusion, 4 doses rituximab, 6 doses aldesleukin and 5 doses fludarabine and 1 dose cyclosphosphamide.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Patients Treated With Natural Killer Cells</title>
          <description>Patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with 1 dose donor natural killer cells infusion, 4 doses rituximab, 6 doses aldesleukin and 5 doses fludarabine and 1 dose cyclosphosphamide.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.2" spread="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Exhibiting Natural Killer Cell Expansion</title>
        <description>Successful natural killer (NK) cell expansion will be defined as an absolute circulating donor-derived NK cell count of &gt;100 cells/μl 14 days after infusion with &lt;5% donor T and B cells in the mononuclear population.</description>
        <time_frame>Day 14</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients Treated With Natural Killer Cells</title>
            <description>Patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with 1 dose donor natural killer cells infusion, 4 doses rituximab, 6 doses aldesleukin and 5 doses fludarabine and 1 dose cyclosphosphamide.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Exhibiting Natural Killer Cell Expansion</title>
          <description>Successful natural killer (NK) cell expansion will be defined as an absolute circulating donor-derived NK cell count of &gt;100 cells/μl 14 days after infusion with &lt;5% donor T and B cells in the mononuclear population.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Interleukin-15 Production and NK Cell Expansion</title>
        <description>Correlation of interleukin-15 production at day 0 with natural killer (NK) cells expansion</description>
        <time_frame>Day 0</time_frame>
        <population>Correlation of interleukin-15 with Natural Killer Cell expansion cannot be calculated because there was no Natural Killer Cell expansion.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients Treated With Natural Killer Cells</title>
            <description>Patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with 1 dose donor natural killer cells infusion, 4 doses rituximab, 6 doses aldesleukin and 5 doses fludarabine and 1 dose cyclosphosphamide.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Interleukin-15 Production and NK Cell Expansion</title>
          <description>Correlation of interleukin-15 production at day 0 with natural killer (NK) cells expansion</description>
          <population>Correlation of interleukin-15 with Natural Killer Cell expansion cannot be calculated because there was no Natural Killer Cell expansion.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Overall Response</title>
        <description>Overall response (complete remission plus partial remission) rate at 3 months, as defined by International Working Group for non-Hodgkin lymphoma and NCI Working Group guidelines for chronic lymphocytic leukemia</description>
        <time_frame>3 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients Treated With Natural Killer Cells</title>
            <description>Patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with 1 dose donor natural killer cells infusion, 4 doses rituximab, 6 doses aldesleukin and 5 doses fludarabine and 1 dose cyclosphosphamide.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Overall Response</title>
          <description>Overall response (complete remission plus partial remission) rate at 3 months, as defined by International Working Group for non-Hodgkin lymphoma and NCI Working Group guidelines for chronic lymphocytic leukemia</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Whose Disease Progressed After Treatment</title>
        <description>Includes patients (with non-Hodgkin leukemia or chronic lymphocytic leukemia) whose disease progressed after treatment.</description>
        <time_frame>6 Months</time_frame>
        <population>Only patients who responded to treatment included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Responder Patients</title>
            <description>Patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with donor natural killer cells infusion, rituximab, aldesleukin and chemotherapy who had a response to treatment (clinical response or partial response).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Whose Disease Progressed After Treatment</title>
          <description>Includes patients (with non-Hodgkin leukemia or chronic lymphocytic leukemia) whose disease progressed after treatment.</description>
          <population>Only patients who responded to treatment included in the analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Adequate Natural Killer Cells Infused</title>
        <description>Incidence of donor products that met release criteria in accordance with FDA regulations (Lot Release Criteria for allogeneic, interleukin-2 (IL-2) activated natural killer (NK) cell products (BB-IND 8847) and the NK cell numbers infused (donor NK cell dose 1.5-8.0 x 10^7/kg).</description>
        <time_frame>Day 0</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients Treated With Natural Killer Cells</title>
            <description>Patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with 1 dose donor natural killer cells infusion, 4 doses rituximab, 6 doses aldesleukin and 5 doses fludarabine and 1 dose cyclosphosphamide.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Adequate Natural Killer Cells Infused</title>
          <description>Incidence of donor products that met release criteria in accordance with FDA regulations (Lot Release Criteria for allogeneic, interleukin-2 (IL-2) activated natural killer (NK) cell products (BB-IND 8847) and the NK cell numbers infused (donor NK cell dose 1.5-8.0 x 10^7/kg).</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Overall Survival</title>
        <description>Number of patients alive at 6 months after treatment.</description>
        <time_frame>6 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients Treated With Natural Killer Cells</title>
            <description>Patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with 1 dose donor natural killer cells infusion, 4 doses rituximab, 6 doses aldesleukin and 5 doses fludarabine and 1 dose cyclosphosphamide.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Overall Survival</title>
          <description>Number of patients alive at 6 months after treatment.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events were collected after start of chemotherapy treatment (Day -1) through date of death (all within 6 months).</time_frame>
      <desc>Stopping Rules for excess toxicity:&#xD;
Any non-hematologic grade 4 toxicity except for fevers alone&#xD;
Grade III/IV GvHD or GvHD requiring more than 7 days of therapy&#xD;
Hematologic toxicity: prolonged neutropenia defined as an absolute neutrophil count of less than 500 on day +35. Prolonged anemia or thrombocytopenia will not constitute toxicity.</desc>
      <group_list>
        <group group_id="E1">
          <title>Patients Treated With Natural Killer Cells</title>
          <description>Patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with 1 dose donor natural killer cells infusion, 4 doses rituximab, 6 doses aldesleukin and 5 doses fludarabine and 1 dose cyclosphosphamide.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <description>ANC &lt;500 at day +35</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Arrhythmia</sub_title>
                <description>Ventricular arrhythmia - Bigeminy</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death - Disease Progression NOS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary - obstruction/stenosis of airway</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study was terminated early due to lack of NK expansion and failure to meet primary outcome.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Veronika Bachanova, M.D.</name_or_title>
      <organization>Masonic Cancer Center, University of Minnesota</organization>
      <phone>612-625-5469</phone>
      <email>bach0173@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

